Exosome Diagnostics Announces Appointment of Vincent J. O'Neill, M.D. As Chief Medical Officer
NEW YORK, June 3, 2014 /PRNewswire/ -- Exosome Diagnostics, a leading developer of non-invasive, biofluid-based molecular diagnostics, today announced that Vincent J. O'Neill, M.D., has been appointed as its chief medical officer.
Dr. O'Neill has extensive experience in clinical trial design, regulatory issues, and personalized medicine, most recently as global head Personalized of Medicine and Companion Diagnostics at Sanofi. At Sanofi, he defined the personalized medicine strategy built the internal infrastructure and designed best practice protocols. He also created alliances and agreements with diagnostic testing laboratories and in vitro diagnostic companies.
Prior to working at Sanofi, Dr. O'Neill managed the clinical development programs of several oncology therapeutic candidates, including biomarker development, at both Genentech and GlaxoSmithkline. He was instrumental in the expanded approval of products such as Avastin® and Tarceva® at Genentech. At GlaxoSmithkline, he managed the signal transduction discovery unit from which the first Investigative New Drug (IND) application and clinical trial, including patient selection strategy, of an MEK inhibitor (Mekinist®) was conducted.
Dr. O'Neill received his BSc in pathology, and his MBChB and M.D. from the University of Glasgow. He is the author of multiple peer reviewed publications and conference presentations on clinical trial design in personalized medicine, novel biomarker-focused clinical trial design in oncology, and maximizing success with patient stratification.
About Exosome Diagnostics
Exosome Diagnostics is a leading developer of fluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are packaged and shed into all biofluids, including blood, urine and cerebrospinal fluid, providing a stable source for intact, disease-specific genetic material. The company's proprietary exosome technology makes use of the presence and natural stability of RNA in exosomes to detect and measure levels of genes responsible for cancer and other diseases. For more information, please visit www.exosomedx.com.
SOURCE Exosome Diagnostics